Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade

Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade

The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:NPJ precision oncology 2022-04, Vol.6 (1), p.23-23, Article 23
Hauptverfasser: Yoo, Seong-Keun, Chowell, Diego, Valero, Cristina, Morris, Luc G. T., Chan, Timothy A.
Format: Artikel
Sprache:eng
Schlagworte:
692/308/409
692/53/2422
692/699/67
Biomarkers
Brief Communication
Cancer Research
Cancer therapies
Gene Therapy
Human Genetics
Immunotherapy
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Targeted cancer therapy
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group.
ISSN:2397-768X
2397-768X
DOI:10.1038/s41698-022-00267-7